What Happened
Shares of Novo Nordisk plummeted by over 16% following disappointing results from clinical trials of its new weight-loss treatment, CagriSema. The drug, which combines cagrilintide and semaglutide, was anticipated to outperform Eli Lilly’s Zepbound but failed to meet expectations in a late-stage study involving 809 participants. CagriSema achieved an average weight loss of 23% after 84 weeks, falling short of the expected 25% and the 25.5% achieved by Zepbound.
Why It Matters
The setback is significant for Novo Nordisk, which has seen its market value decline by £350 billion, returning to levels last seen in June 2021. The company had previously enjoyed a surge in stock prices due to the success of its blockbuster drug Wegovy. Analysts are now questioning whether the disappointing trial results will impact Novo’s decision to launch CagriSema, with some describing the situation as a ‘swing and a miss.’
What’s Next
As Novo Nordisk grapples with this setback, the company faces an uphill battle against Eli Lilly in the competitive weight-loss drug market. Investors are closely monitoring the situation, as the results of the trial have raised concerns about Novo’s ability to maintain its position in the industry. The future of CagriSema remains uncertain as the company evaluates its next steps.
